Molidustat Tablets – HIF-PH Inhibitor for Anemia Management in Cats with Chronic Kidney Disease (CKD)
Molidustat Tablets – HIF-PH Inhibitor for Anemia Management in Cats with Chronic Kidney Disease (CKD)
Molidustat Tablets – HIF-PH Inhibitor for Anemia Management in Cats with Chronic Kidney Disease (CKD)
Molidustat Tablets – HIF-PH Inhibitor for Anemia Management in Cats with Chronic Kidney Disease (CKD)
Molidustat Tablets – HIF-PH Inhibitor for Anemia Management in Cats with Chronic Kidney Disease (CKD)
Molidustat Tablets – HIF-PH Inhibitor for Anemia Management in Cats with Chronic Kidney Disease (CKD)
Molidustat Tablets – HIF-PH Inhibitor for Anemia Management in Cats with Chronic Kidney Disease (CKD)
Molidustat Tablets – HIF-PH Inhibitor for Anemia Management in Cats with Chronic Kidney Disease (CKD)

Molidustat Tablets – HIF-PH Inhibitor for Anemia Management in Cats with Chronic Kidney Disease (CKD)

Price
Regular price $29900
Regular price Sale price $29900
Save $-299
/
Shipping calculated at checkout.
  • Low stock - 5 items left
  • Backordered, shipping soon
  • Worldwide Shipping
  • Fast Delivery
  • 14-Days Money Back Guarantee
  • Secure Checkout

Pairs well with

Molidustat is a next-generation hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, developed to stimulate endogenous erythropoietin (EPO) production. In feline medicine, Molidustat is increasingly explored off-label to support the management of non-regenerative anaemia associated with Chronic Kidney Disease (CKD) in cats.

By promoting physiologic red blood cell production rather than replacing EPO externally, Molidustat offers a novel, oral approach for long-term anemia support when used under strict veterinary guidance.

Molidustat inhibits prolyl hydroxylase enzymes, stabilising HIF-α (Hypoxia-Inducible Factor) under normal oxygen conditions. This leads to:

  • Increased endogenous erythropoietin (EPO) production

  • Enhanced iron metabolism and utilisation

  • Stimulation of erythropoiesis in bone marrow

Unlike injectable recombinant EPO, Molidustat promotes a more physiologic and sustained erythropoietic response.
⭐ Key Benefits

🐾 Supports anaemia management in CKD cats

💊 Oral administration – no injections required

🧬 Encourages natural EPO production

📈 May reduce dependence on recombinant erythropoietin

🩸 Supports improved hematocrit and red blood cell counts

🔄 Suitable for long-term management under veterinary monitoring
💊 Usage & Dosage

Cats diagnosed with Chronic Kidney Disease (IRIS Stage 2–4)

CKD-related non-regenerative anaemia

Cats intolerant or unresponsive to injectable EPO therapies

Adjunct to renal diet, phosphate binders, and supportive CKD care

Dosage must be individualised by a veterinarian based on:

Body weight

CKD stage

Hematocrit / PCV

Iron status

Blood pressure

Published experimental and clinical reports suggest:

Starting dose: ~1 - 2 mg/kg orally once daily

Maintenance dose: Adjusted based on haematological response
⚠️ Side Effects

Possible adverse effects (dose-dependent and patient-specific) may include:

Increased blood pressure (hypertension)

Gastrointestinal upset (vomiting, decreased appetite)

Elevated hematocrit if overdosed

Thromboembolic risk with excessive erythropoiesis

Changes in liver enzymes (rare)
You may also like